Livrables
D64 Recommendations for data reproducibility training M36 EUOS
Improved protocols for compound sourcing and acquisition based on EU-OS Ambassador feedback, including a directory of cooperating chemists from each countryD2.1 Improved protocols for compound sourcing and acquisition based on EU-OS Ambassador feedback, including a directory of cooperating chemists from each country (M12) (UH, USC)
Report on implementation of enhanced transfer procedures for data from EU-OS partner sitesD62 Report on implementation of enhanced transfer procedures for data from EUOS partner sites M55 EUOS
Publication describing the performance of the fragment library in screening campaignsD42 Publication describing the performance of the fragment library in screening campaigns M40 OSI EMBL
Report on scientific publications and dissemination / outreach activities to new communitiesD93 Report on scientific publications and dissemination outreach activities to new communities M56 EUOS
Gender action planD9.2 Gender action plan (M12) (EU-OS)
Report on outcomes of the chemical optimisation projectsD32 Report on outcomes of the chemical optimisation projects including of gaps in medicinal chemistry services and recommendation for process improvements for EUOS operation M55 EUOS
Mode of action or compound distribution report for compounds from selected projects from phase 1 (responsibility of sites providing access)D51 Mode of action or compound distribution report for compounds from selected projects from phase 1 responsibility of sites providing access M33 IME
Mode of action or compound distribution report for compounds from selected projects from phase 2 (responsibility of sites providing access)D52 Mode of action or compound distribution report for compounds from selected projects from phase 2 responsibility of sites providing access M48 IME
Report on the status of co-developed screening technologiesD72 Report on the status of codeveloped screening technologies M56 USC UiO
Report on available courses relevant for users and staff of EU-OSD8.1 Report on available courses relevant for users and staff of EU-OS (M12) (IMG)
Report on outcomes of the screening projectsD31 Report on outcomes of the screening projects including identification of gaps in screening services and recommendation for process improvements for EUOS operation M35 EUOS
Report on improvements to the access and workflows.D1.1 Report on improvements to the access and workflows (M12) (EU-OS)
Innovation management planD73 Innovation management plan M56 USC UiO
Report on the translation module for EU-OS screening centresD63 Report on the translation module for EUOS screening centres M55 EUOS
FBDD chemical evolution consultation service guidelinesD4.1 FBDD chemical evolution consultation service guidelines (M12) (OSI, HZI)
Management guidelinesD9.1 Management guidelines (M2) (EU-OS)
Report on engagement measures and successes for extension of EU-OS membershipD13 Report on engagement measures and successes for extension of EUOS membership M55 EUOS
Enhanced Business Plan and financial sustainability model based on EU-OS-DRIVE outcomesD15 Enhanced Business Plan and financial sustainability model based on EUOSDRIVE outcomes M56 EUOS
Data Management PlanD6.5 Data Management Plan (M6) (EU-OS)
Final report on the EU-OS academic compound libraryD23 Final report on the EUOS academic compound library to include metrics on compound acquisition quality diversity uniqueness etc summaries of training events organized and recommendations for future acquisition campaigns M56 UH USC
Report on report on sustainability aspects and future perspectives for forming major strategic cooperations in the fields of chemical biology and academic drug discovery. Audiences are policy makers and funding bodiesD94 Report on report on sustainability aspects and future perspectives for forming major strategic cooperations in the fields of chemical biology and academic drug discovery Audiences are policy makers and funding bodies M57 EUOS
Report on co-ordination of joined training with other BMS ESFRI projects and establishing new collaborative linksD8.3 Report on co-ordination of joined training with other BMS ESFRI projects and establishing new collaborative links (M18) (IMG)
Report on existing data transfer procedures and gap analysisD6.1 Report on existing data transfer procedures and gap analysis (M6) (EU-OS)
Report on the evaluation of tools to improve compound registrationD2.2 Report on the evaluation of tools to improve compound registration (M18) (UH, USC)
Roadmap for industry interactions and establishment of industry involvement in EU-OS’s activitiesD7.1 Roadmap for industry interactions and establishment of industry involvement in EU-OS’s activities (M8) (USC, UiO)
Report on newly developed courses organized by EU-OS-DRIVED8.2 Report on newly developed courses organized by EU-OS-DRIVE (M18) (IMG)
Handbook and defined user workflows for two new categories of partner sitesD12 Handbook and defined user workflows for two new categories of partner sites M46 EUOS
D9.5 Delivery of periodic, mid-term and final reports (M12, 24, 36, 48) (EU-OS) due M12, M24, M36, M48
Socio-economic impact study and documented refined KPIsD1.4 Socio-economic impact study and documented refined KPIs (M56) (EU-OS)
Note The Assay Providing User may request an optional grace period which allows for an indepth characterisation of the identified compounds and facilitates the publication of research findings in highlevel peerreviewed journals or the application for a patent If an IP position is being sought then a grace period of up to 24 month with the possibility to extend to 36 months in exceptional circumstances may be granted These grace periods align with current practice of other initiatives eg the IMI European Lead Factory which plans to release the Qualifiedhitlists of their projects after a defined grace period
Publications
Auteurs:
Schuller, Marion
Correy, Galen J.
Gahbauer, Stefan
Fearon, Daren
Wu, Taiasean
Díaz, Roberto Efraín
Young, Iris D.
Martins, Luan Carvalho
Smith, Dominique H.
Schulze-Gahmen, Ursula
Owens, Tristan W.
Deshpande, Ishan
Merz, Gregory E.
Thwin, Aye C.
Biel, Justin T.
Peters, Jessica K.
Moritz, Michelle
Herrera, Nadia
Kratochvil, Huong T.
Aimon, Anthony
Bennett, James M.
Neto, Jose Brandao
Cohen, Aina
Publié dans:
Science Advances, Numéro Vol 7, Numéro 16, 2021, Page(s) eabf8711, ISSN 2375-2548
Éditeur:
American Association for the Advancement of Science
DOI:
10.1126/sciadv.abf8711
Auteurs:
Pau Martin-Malpartida, Emil Hausvik, Jarl Underhaug, CarlesTorner, AuroraMartinez, Maria J.Macias
Publié dans:
JMB Journal of Molecular Biology, Numéro Volume 434, Numéro 11, 15 June 2022, 167372, 2022, ISSN 0022-2836
Éditeur:
Academic Press
DOI:
10.1016/j.jmb.2021.167372
Auteurs:
Alessandra Silvestri, Francisca Vicente, María J.Vicent, Bahne Stechmann, Wolfgang Fecke
Publié dans:
Drug Discovery Today, Numéro Volume 26, Numéro 6, June 2021, 2021, Page(s) Pages 1369-1381, ISSN 1359-6446
Éditeur:
Elsevier BV
DOI:
10.1016/j.drudis.2021.02.024
Auteurs:
Tiziana Ginex; Enrique Madruga; Ana Martinez; Carmen Gil
Publié dans:
Frontiers in Pharmacology, Numéro Volume 14 - 2023, 2023, ISSN 1663-9812
Éditeur:
Frontiers Media S.A.
DOI:
10.3389/fphar.2023.1244317
Auteurs:
Zoraida Andreu; Esther Masiá; David Charbonnier; María J. Vicent
Publié dans:
Nanotheranostics, Numéro 2023 Jan 1;7(1):1-21., 2023, ISSN 2206-7418
Éditeur:
Ivyspring International Publisher
DOI:
10.7150/ntno.73606
Auteurs:
Stephanie Merz
Publié dans:
2022
Éditeur:
TU Darmstadt, Germany
Recherche de données OpenAIRE...
Une erreur s’est produite lors de la recherche de données OpenAIRE
Aucun résultat disponible